<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01118221</url>
  </required_header>
  <id_info>
    <org_study_id>O7467-R</org_study_id>
    <nct_id>NCT01118221</nct_id>
  </id_info>
  <brief_title>Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients</brief_title>
  <official_title>Rehabilitation of IPF Patients: Effects of Exercise and Oxidant Stress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence and prevalence of IPF increase exponentially with age, and IPF occurs more&#xD;
      often in older males. Cigarette smoking and environmental dust exposures are known risk&#xD;
      factors for developing IPF. For example, the recently deployed military population, as it&#xD;
      ages, is at especially increased risk of IPF. No effective therapies exist, although lung&#xD;
      transplantation is used to extend survival of selected patients.&#xD;
&#xD;
      Defining specific therapy to improve exercise tolerance and dyspnea in IPF patients is thus&#xD;
      an urgent priority of veteran-oriented research programs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic lung disease is common in the veteran population. While chronic obstructive pulmonary&#xD;
      disease (COPD) is most prominent, fibrotic lung diseases, typified by idiopathic pulmonary&#xD;
      fibrosis (IPF), are clearly increasing. We have developed extensive experience with a VA&#xD;
      idiopathic pulmonary fibrosis (IPF) population in the context of a randomized, controlled&#xD;
      clinical trial of vasodilator therapy.&#xD;
&#xD;
      Based on the current literature and our preliminary experience with exercise testing in IPF&#xD;
      patients, we hypothesize that:&#xD;
&#xD;
        1. Formal pulmonary rehabilitation (i.e., an aerobic exercise program) will result in&#xD;
           improved outcomes for IPF patients, demonstrable as an:&#xD;
&#xD;
             1. Increase in exercise tolerance as quantified by 6-minute walk test (MWT) distance;&#xD;
&#xD;
             2. Decrease in post-exercise dyspnea as quantified by the Borg dyspnea scale; and an&#xD;
&#xD;
             3. Overall subjective improvement in quality of life as quantified by Saint George's&#xD;
                Respiratory Questionnaire.&#xD;
&#xD;
        2. Metabolic and physiologic mechanisms of improved exercise tolerance and decreased&#xD;
           dyspnea will include:&#xD;
&#xD;
             1. More efficient oxygen metabolism demonstrated by maximum O2 uptake (VO2max);&#xD;
&#xD;
             2. Decreased post-exercise oxidant stress demonstrated by post-exercise isoprostanes&#xD;
                and plasma total antioxidant capacity (TAC); and,&#xD;
&#xD;
             3. Maintenance of maximum inspiratory and expiratory pressures (PInmax and PExmax).&#xD;
&#xD;
      Our Specific Objectives are:&#xD;
&#xD;
        1. To investigate formal pulmonary rehabilitation and exercise tolerance in IPF patients&#xD;
&#xD;
           The following important endpoints will be assessed to test the working hypothesis that&#xD;
           pulmonary rehabilitation improves exercise capacity and lessens dyspnea:&#xD;
&#xD;
             1. 6-MWT distance;&#xD;
&#xD;
             2. Dyspnea index; and,&#xD;
&#xD;
             3. Quality of life (Saint George's Respiratory Questionnaire [SGRQ] and International&#xD;
                Physical Activity Questionnaire [IPAQ]).&#xD;
&#xD;
        2. To assess changes in oxygen uptake, markers of oxidant stress and pulmonary function&#xD;
           resulting from pulmonary rehabilitation&#xD;
&#xD;
      To test the working hypothesis that improved outcomes are associated with more efficient O2&#xD;
      utilization, decreased markers of oxidant stress and maintained effort dependent pulmonary&#xD;
      function, the following variables will be measured:&#xD;
&#xD;
        1. Peak oxygen uptake (VO2peak) during constant load exercise;&#xD;
&#xD;
        2. Markers of oxidant stress, including plasma and urine isoprostanes; and,&#xD;
&#xD;
        3. Maximum inspiratory and expiratory pressures (PInmax and PExmax). Completion of these&#xD;
           Specific Objectives will position our research group to conduct future studies of 1)&#xD;
           mechanisms of exercise limitation and 2) antioxidant therapies, both in this defined&#xD;
           population and those who are at risk of developing pulmonary fibrosis. The long term&#xD;
           impact of this application is thus to develop effective pulmonary rehabilitation&#xD;
           strategies for IPF patients, based on knowledge of underlying changes in oxygen&#xD;
           metabolism and oxidant stress.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 Minute Walk Distance</measure>
    <time_frame>The 6-MWD will be measured at 0 and 3 months.</time_frame>
    <description>Change in 6 Minute Walk Distance from Baseline to 3 Months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic Markers of Oxidant Stress</measure>
    <time_frame>Markers of oxidant stress will be measured in all subjects before randomization after exercise testing at 0 months.</time_frame>
    <description>Plasma F2-isoprostanes measured in all subjects before and after exercise testing at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Oxygen Uptake</measure>
    <time_frame>Maximum O2 uptake will be measured at 0 and 3 months.</time_frame>
    <description>Change in 6 peak O2 uptake from Baseline to 3 Months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enroll in pulmonary rehabilitation program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no structured exercise</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>pulmonary rehabilitation</intervention_name>
    <description>structured exercise program</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical presentation consistent with IPF with onset between three months and 48&#xD;
             months prior to screening.&#xD;
&#xD;
          -  Diagnosis made by high-resolution computed tomographic scan showing highly probable&#xD;
             IPF.&#xD;
&#xD;
          -  Absence of severe pulmonary hypertension (i.e., PAsys must be less than 55 mm Hg,&#xD;
             based on echocardiography) and absence of decompensated right heart failure (NYHA&#xD;
             class I or II acceptable).&#xD;
&#xD;
          -  Age 40 through 80, inclusive.&#xD;
&#xD;
          -  Abnormal pulmonary function tests (FVC 40-90% predicted or DLCO 30-90% predicted or&#xD;
             impaired gas exchange with rest or exercise).&#xD;
&#xD;
          -  Six-minute walk distance 150 m and 500 m.&#xD;
&#xD;
          -  Worsening as demonstrated by any one of the following within the past year: &gt; 10%&#xD;
             decrease in percent predicted forced vital capacity or worsening dyspnea at rest or&#xD;
             upon exertion, based on history.&#xD;
&#xD;
          -  Ability to understand and sign a written informed consent form and comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
          -  Absence of clinical features suggesting infection, neoplasm, sarcoidosis or&#xD;
             collagen-vascular disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Echocardiographic evidence of severe pulmonary hypertension (PAsys&gt;55 mm Hg, based on&#xD;
             echocardiography or TR velocity 3.2 m/sec).&#xD;
&#xD;
          -  Severe heart failure (NYHA class III or IV or LVEF &lt; 45%).&#xD;
&#xD;
          -  Six-minute walk distance &lt; 150 m or &gt; 500 m.&#xD;
&#xD;
          -  FEV1/FVC ratio &lt; 0.7 at screening (post-bronchodilator).&#xD;
&#xD;
          -  Residual volume &gt; 100% predicted.&#xD;
&#xD;
          -  Any condition other than IPF likely to result in the death of the participant within&#xD;
             the next two years.&#xD;
&#xD;
          -  History of unstable or deteriorating cardiac or neurologic disease.&#xD;
&#xD;
          -  Pregnancy or lactation. Patients who are: (a) pregnant or (b) breast feeding are&#xD;
             excluded from the study.&#xD;
&#xD;
          -  Current treatment with corticosteroids (either oral or inhaled), Cytoxan,&#xD;
             azathioprine, colchicine, pirfenidone, anti-tumor necrosis factor therapy or&#xD;
             endothelin receptor blockers. Prior treatment is permitted, but at least four weeks of&#xD;
             treatment washout prior to inclusion in this study are required.&#xD;
&#xD;
          -  Investigational therapy for any indication within 28 days prior to enrollment.&#xD;
&#xD;
          -  Degenerative arthritis, cerebrovascular accident or other limitation to mobility&#xD;
             preventing completion of the 6-minute walk test.&#xD;
&#xD;
          -  Oxygen saturation on room air &lt;80% at rest.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert M Jackson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jackson RM, Gómez-Marín OW, Ramos CF, Sol CM, Cohen MI, Gaunaurd IA, Cahalin LP, Cardenas DD. Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation. Lung. 2014 Jun;192(3):367-76. doi: 10.1007/s00408-014-9566-9. Epub 2014 Apr 5.</citation>
    <PMID>24705678</PMID>
  </results_reference>
  <results_reference>
    <citation>Gaunaurd IA, Gómez-Marín OW, Ramos CF, Sol CM, Cohen MI, Cahalin LP, Cardenas DD, Jackson RM. Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program. Respir Care. 2014 Dec;59(12):1872-9. doi: 10.4187/respcare.03180. Epub 2014 Sep 2.</citation>
    <PMID>25185149</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>April 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2010</study_first_posted>
  <results_first_submitted>November 19, 2014</results_first_submitted>
  <results_first_submitted_qc>December 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2015</results_first_posted>
  <last_update_submitted>February 13, 2015</last_update_submitted>
  <last_update_submitted_qc>February 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oxidant stress</keyword>
  <keyword>exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pulmonary Rehabilitation</title>
          <description>enroll in pulmonary rehabilitation program&#xD;
pulmonary rehabilitation: structured exercise program</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>no structured exercise</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pulmonary Rehabilitation</title>
          <description>enroll in pulmonary rehabilitation program&#xD;
pulmonary rehabilitation: structured exercise program</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>no structured exercise</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" spread="6"/>
                    <measurement group_id="B2" value="66" spread="7"/>
                    <measurement group_id="B3" value="69" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>6 Minute Walk Distance</title>
        <description>Change in 6 Minute Walk Distance from Baseline to 3 Months</description>
        <time_frame>The 6-MWD will be measured at 0 and 3 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>enroll in pulmonary rehabilitation program&#xD;
pulmonary rehabilitation: structured exercise program</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>no structured exercise</description>
          </group>
        </group_list>
        <measure>
          <title>6 Minute Walk Distance</title>
          <description>Change in 6 Minute Walk Distance from Baseline to 3 Months</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="86.9"/>
                    <measurement group_id="O2" value="-15.3" spread="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Markers of Oxidant Stress</title>
        <description>Plasma F2-isoprostanes measured in all subjects before and after exercise testing at baseline.</description>
        <time_frame>Markers of oxidant stress will be measured in all subjects before randomization after exercise testing at 0 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Before Exercise Testing</title>
            <description>Plasma isoprostanes before exercise test.</description>
          </group>
          <group group_id="O2">
            <title>After Exercise Testing</title>
            <description>Plasma isoprostanes after exercise testing.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Markers of Oxidant Stress</title>
          <description>Plasma F2-isoprostanes measured in all subjects before and after exercise testing at baseline.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.48" spread="10.10"/>
                    <measurement group_id="O2" value="17.96" spread="10.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Oxygen Uptake</title>
        <description>Change in 6 peak O2 uptake from Baseline to 3 Months</description>
        <time_frame>Maximum O2 uptake will be measured at 0 and 3 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rehabilitation Group</title>
            <description>enroll in pulmonary rehabilitation program&#xD;
pulmonary rehabilitation: structured exercise program</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>no structured exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Oxygen Uptake</title>
          <description>Change in 6 peak O2 uptake from Baseline to 3 Months</description>
          <units>mL/minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35" spread="71"/>
                    <measurement group_id="O2" value="-119" spread="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Six months.</time_frame>
      <desc>Adverse and unexpected events were recorded.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>enroll in pulmonary rehabilitation program&#xD;
pulmonary rehabilitation: structured exercise program</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>no structured exercise</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert M Jackson, MD</name_or_title>
      <organization>MVAHS</organization>
      <phone>305-575-3548</phone>
      <email>robert.jackson4@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

